2020 - Fellow of the American Association for the Advancement of Science (AAAS)
His scientific interests lie mostly in Immunology, FOXP3, Antigen, Immune system and IL-2 receptor. The study of Immunology is intertwined with the study of Cytotoxic T cell in a number of ways. His FOXP3 research incorporates themes from Cancer research, Bacterial antigen and Immunotherapy.
His studies deal with areas such as Cancer and Antibody as well as Antigen. His Immune system research focuses on Monoclonal antibody and how it relates to Peripheral blood mononuclear cell. His study in IL-2 receptor is interdisciplinary in nature, drawing from both Interleukin 21, CD8 and T lymphocyte.
Hiroyoshi Nishikawa spends much of his time researching Immunology, Cancer research, Immune system, Antigen and Internal medicine. His Immunology study integrates concerns from other disciplines, such as Cytotoxic T cell and Cancer. His work carried out in the field of Cytotoxic T cell brings together such families of science as T cell and Molecular biology.
His Cancer research study incorporates themes from Tumor microenvironment, Blockade and CD8, Tumor-infiltrating lymphocytes. The Immune system study combines topics in areas such as Peripheral blood mononuclear cell and Monoclonal antibody. His biological study spans a wide range of topics, including Antibody, Virology, Tumor antigen and NY-ESO-1.
Hiroyoshi Nishikawa mainly investigates Cancer research, Internal medicine, CD8, Oncology and Immune system. Hiroyoshi Nishikawa combines subjects such as Tumor microenvironment, Cancer, Blockade and Cytotoxic T cell with his study of Cancer research. His work investigates the relationship between Internal medicine and topics such as Gastroenterology that intersect with problems in Monoclonal.
His CD8 study is associated with Antigen. His study in FOXP3, Cancer immunotherapy and Immunotherapy falls under the purview of Immune system. FOXP3 connects with themes related to Cell type in his study.
Hiroyoshi Nishikawa spends much of his time researching Cancer research, Immune system, CD8, Tumor microenvironment and Internal medicine. His Cancer research research integrates issues from Immune checkpoint, Immunotherapy, Immunohistochemistry, Cytotoxic T cell and Effector. His research related to Cancer immunotherapy and FOXP3 might be considered part of Immune system.
His FOXP3 study combines topics from a wide range of disciplines, such as Cell type, Immune tolerance, Antibody-dependent cell-mediated cytotoxicity and Immunosurveillance. His CD8 study combines topics in areas such as T cell and Blockade. His Internal medicine research incorporates elements of Gastroenterology and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
Eiichi Sato;Sara H. Olson;Jiyoung Ahn;Brian Bundy.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Koji Atarashi;Takeshi Tanoue;Kenshiro Oshima;Wataru Suda.
Regulatory T cells in tumor immunity
Hiroyoshi Nishikawa;Shimon Sakaguchi;Shimon Sakaguchi.
International Journal of Cancer (2010)
Regulatory T cells in cancer immunotherapy.
Hiroyoshi Nishikawa;Shimon Sakaguchi.
Current Opinion in Immunology (2014)
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Yosuke Togashi;Kohei Shitara;Hiroyoshi Nishikawa.
Nature Reviews Clinical Oncology (2019)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama;Hiroyoshi Nishikawa;Yuka Maeda;Megumi Nishioka.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Two FOXP3 + CD4 + T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito;Hiroyoshi Nishikawa;Hisashi Wada;Yuji Nagano.
Nature Medicine (2016)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada;Yosuke Togashi;Christopher Tay;Danbee Ha.
Proceedings of the National Academy of Sciences of the United States of America (2019)
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
Masanori Matsumoto;Akemi Baba;Takafumi Yokota;Hiroyoshi Nishikawa.
NY-ESO-1: review of an immunogenic tumor antigen.
Sacha Gnjatic;Hiroyoshi Nishikawa;Achim A Jungbluth;Ali O Güre.
Advances in Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: